BEYOND2020 ENHANCES WATER ACCESS FOR 18,000 FILIPINOS IN UPLAND RURAL AREAS

Beyond2020 Philippines (Photo: AETOSWire)

· The latest deployment significantly improves the livelihoods of two upland communities by securing a 24/7 reliable water supply using carbon-neutral technology

ABU DHABI, United Arab Emirates, Dec 16 (Bernama-BUSINESS WIRE) — Beyond2020 returns to Southeast Asia following key sustainable engagements in Indonesia and Cambodia, with a deployment that is uplifting the lives of 18,000 people in The Philippines by enhancing water access and reducing water costs by 85%. Four hydraulic ram pumps and 13 kiosks are being used to impact 3,000 residents in the village of Cabagnaan in the Province of Negros Occidental and 15,000 people in 14 villages across Altavista in the Province of Leyte.

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20211215005619/en/

The innovative technology is an enhancement of a system created more than 240 years ago that brings water uphill without the use of electricity or fuel and the emission of harmful gasses.

Launched by the Zayed Sustainability Prize in partnership with several leading organisations, the Beyond2020 initiative exemplifies the humanitarian legacy of the UAE’s founding father, the late Sheikh Zayed bin Sultan Al Nahyan by donating sustainable technologies and solutions to vulnerable communities worldwide. The Philippines marks the tenth deployment of Beyond2020, which effectively addresses some of the world’s most pressing sustainable development challenges, providing quality healthcare, nutritious food, essential energy, and access to safe water for drinking and sanitation.

H.E. Mohammed Obaid Al Zaabi, UAE Ambassador to the Philippines, said: “As a wide-reaching humanitarian initiative spearheaded by the UAE government and its wise leadership to drive sustainable economic growth globally, Beyond2020 offers crucial and life-transforming solutions to beneficiaries worldwide. The initiative’s deployment in the Philippines offers communities innovative water technology solutions that aim to improve the health and wellbeing of rural residents through long-term impact, paving the way for an easier, safer and more sustainable lifestyle.”

H.E. Al Zaabi added, “The UAE and the Philippines share a common vision towards building a more prosperous and sustainable future for their people, in accordance with the UN’s Sustainable Development Goals. Moreover, the collaboration complements our historically close bilateral relations across multiple avenues. By tackling water scarcity, the drive to further optimise a vital resource for the benefit of communities in the Philippines, also coincides with the recent launch of the UAE’s ‘Principles of the 50’ that seek to stimulate socio-economic growth through humanitarian aid. They are important guiding principles inspired by the enduring legacy of the UAE’s founding father, the late Sheikh Zayed, based on his core values of sustainability, humanitarianism and global cooperation.”

The communities of Cabagnaan and Altavista, that are located on different islands, share the same challenges, whereby water is not available and has to be fetched from a source located further downhill from the community. The deployment utilises a holistic ram pump water system by the Alternative Indigenous Development Foundation, Inc. (AIDFI), a 2020 Zayed Sustainability Prize finalist under the ‘Water’ category.

The Philippines Ambassador to the UAE, H.E. Hjayceelyn M. Quintana added, “We are pleased to see the introduction of these essential, environmentally-friendly and life-changing solutions by the Beyond2020 initiative. The notable reach and impact of the technology supports the Philippine government’s drive to improve public services and the health of our citizens, with water being a key priority for social welfare and sustainable development.”

“We are confident that the mobilisation of international action that empowers and supports our communities’ ability to access and manage water resources will promote widespread benefits to the daily lives of impacted beneficiaries. We therefore extend our gratitude to the initiative and its partners whose involvement has been central to the realisation of the project on the ground today.”

H.E. Ólafur Grímsson, Chair of the Zayed Sustainability Prize Jury and former President of the Republic of Iceland, said, “Beyond2020’s latest project in the Philippines demonstrates the power of leveraging an innovative solution by our global community of winners and finalists and exploring its long-term capacity for beneficiaries. The initiative also demonstrates the power of collaboration as the Prize and its partners have impacted communities in 10 countries to-date, with further deployments scheduled for 2022.”

In addition to providing clean water for drinking and sanitation, the carbon-neutral technology offers residents the opportunity to improve or pursue water-related livelihoods such as vegetable gardens, aquaculture, and livestock breeding, while facilitating a more conducive environment to avoid several waterborne diseases stemming from dirty water. Furthermore, access to improved hygiene grows in prominence given the importance of handwashing in preventing the spread of COVID-19, a pressing concern for vulnerable communities worldwide.

Ten deployments have been rolled out to date under the umbrella of Beyond2020, with another nine in progress. Completed deployments include vital energy, health, water and food-related solutions in Nepal, Tanzania, Uganda, Jordan, Egypt, Cambodia, Madagascar, Indonesia, Bangladesh, and The Philippines.

Beyond2020 brings together a leading number of partners which include Abu Dhabi Fund for Development, Mubadala Petroleum and Masdar.

For more on the Prize, visit: https://zayedsustainabilityprize.com/

*Source: AETOSWire

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211215005619/en/

Contact

Medhat Juma
Hill+Knowlton Strategies
T: +971 561399482
Medhat.Juma@hkstrategies.com

Erika Spagakou
Hill+Knowlton Strategies
T: +971 551398765
Erika.Spagakou@hkstrategies.com

Source : Zayed Sustainability Prize

–BERNAMA

ADAGIO THERAPEUTICS PROVIDES UPDATE FOLLOWING EXTERNAL IN VITRO ANALYSES

KUALA LUMPUR, Dec 15 (Bernama) — Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company, has provided an update following external in vitro analyses to evaluate neutralising activity of ADG20 against the Omicron SARS-CoV-2 variant.

The in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300-fold reduction in neutralising activity of ADG20 against Omicron, according to a statement.

Additional analyses are ongoing, and the company plans to engage with regulatory and government agencies to assess the role ADG20 can play for the prevention and treatment of COVID-19, particularly as the industry’s understanding of the epidemiology and impact of Omicron and potential new variants develops.

“Due to the highly conserved and immunorecessive nature of the epitope recognised by ADG20, we anticipated that ADG20 would retain neutralising activity against Omicron, consistent with activity observed in in vitro models with all other known variants of concern,” said Tillman Gerngross, Ph.D., chief executive officer of Adagio.

ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralising activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year with a single injection.

In previously disclosed in vitro studies, ADG20 retained activity against prior variants of concern including Alpha, Beta, Delta and Gamma.

In addition, in vitro data demonstrated retained neutralising activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the Lambda, Mu and Delta plus variants.

The safety and efficacy of ADG20 have not been established, and ADG20 is not authorised or approved for use in any country. Adagio is currently evaluating ADG20 in global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19.

More details at http://www.adagiotx.com.

— BERNAMA

AGC BIOLOGICS PARTNERS I-MAB BIOPHARMA SUPPORTING LATE-STAGE CLINICAL TRIALS

KUALA LUMPUR, Dec 14 (Bernama) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new partnership with I-MAB Biopharma.

The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.

AGC Biologics operates multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle cell culture facility.

The site is designed for capacity and technological flexibility, and has an extensive variety of single-use and stainless steel systems that meet the latest guidelines required for cGMP compliance, with the Seattle site having a long history of successful inspections by the FDA and approved for commercial production.

Based on a statement, these features and capabilities combined make the AGC Biologics Seattle facility an ideal location to support I-MAB’s goals and bring this treatment through its next clinical phase.

“We look forward to partnering with a true pioneer in innovative clinical research and development, and working together to help bring I-MAB’s product through the final clinical stages and to commercialisation,” said Jean-Baptiste Agnus, Chief Business Officer of AGC Biologics.

“Our team in Seattle is an ideal customer-focused group of scientists to help I-MAB in its promising journey for this treatment.”

AGC Biologics’ Seattle facility has capabilities for developing a wide range of mammalian and microbial programs, and has delivered several approved commercial products. Its global network spans the US, Europe, and Asia.

To learn more, visit http://www.agcbio.com.

ADAGENE UNVEILS PRECLINICAL DATA AT 63RD AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

KUALA LUMPUR, Dec 14 (Bernama) — Biopharmaceutical company, Adagene Inc (Adagene), has announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE).

The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place Dec 11-14, 2021 which are available in the Publications section of the company’s website, according to a statement.

“Our novel anti-CD47 antibody and CD20xCD3 bispecific TCE programs successfully leverage SAFEbody technology for precision masking to decouple efficacy from the toxicities that are often associated with therapeutic modalities for these two important targets on the forefront of clinical development for hematologic malignancies,” said Adagene Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D.

“Our preclinical evaluation shows the desirable target product profiles of these two transformative programs emerging from our deep, broad and differentiated pipeline.”

The poster (#3342) titled ‘ADG153, an Anti-CD-47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass’.

Key findings from the poster include given the dose-limiting hematologic toxicity and antigen sink liability associated with current anti-CD47 antibodies in clinical development, Adagene has developed an anti-CD47 SAFEbody with precision masking for preferential binding on CD47 overexpressed on tumour versus normal cells.

Meanwhile, the poster (#1204) titled ‘ADG152, a Novel CD20xCD3 T-Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety’.

Key findings from the poster include ADG152 is a bispecific CD20xCD3 T-cell engager POWERbody that integrates SAFEbody precision masking technology to minimise cytokine release syndrome (CRS) and on-target/off-tumour toxicities for an increased therapeutic index.

Both ADG153 and ADG152 are potential Investigational New Drug candidates from Adagene’s growing portfolio of preclinical discovery programs, five of which are in IND-enabling studies.

The preclinical data presented at ASH provide a strong rationale for advancing these potentially best-in-class candidates into clinical development.

More details at http://www.adagene.com.

— BERNAMA

PRESTIGE BIOPHARMA AND DR. REDDY’S ANNOUNCE PARTNERSHIP TO COMMERCIALIZE TRASTUZUMAB BIOSIMILAR IN SELECT COUNTRIES IN LATIN AMERICA AND SOUTHEAST ASIA

SINGAPORE & HYDERABAD, India, Dec 9 (Bernama-BUSINESS WIRE) — Prestige BioPharma Ltd. (KRX: 950210) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.

Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin® and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer. Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

The license agreement grants Dr. Reddy’s the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia. Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.

Lisa S. Park, CEO of Prestige BioPharma, commented: “We are delighted to establish a partnership with Dr. Reddy’s for key Latin American and Southeast Asian markets. Dr. Reddy’s is the ideal partner to commercialize our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.”

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, said: “In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need. Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets. This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets.”

About Prestige BioPharma Limited:
PRESTIGE BIOPHARMA LTD (PBP) is a Singapore-based biopharmaceutical company with operations in USA and Korea, specialising in the discovery and development of biosimilars, novel antibodies and vaccines. PBP strives to become a global innovator through the development of first-in-class mAbs including PBP1510 anti-PAUF mAb for pancreatic cancer that recently obtained orphan designation from FDA, EMA and MFDS. PBP’s rich portfolio of biosimilars in various stages including HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need. PBP’s business also includes alliance vaccine development and production, starting with the partnered commercial production of COVID-19 vaccines. For more information, please visit www.prestigebiopharma.com.

About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211208006176/en/

Contact

Prestige BioPharma Limited

Investor Relations
Bumjoon Kim
Bumjoon.kim@pbpsg.com

Corporate Communication
Yujin Suh
yujin.suh@pgpsg.com

Dr. Reddy’s Laboratories Ltd.

Investor Relations
Amit Agarwal
amita@drreddys.com

Corporate Communication
Usha Iyer
ushaiyer@drreddys.com

Source : Dr. Reddy’s Laboratories Ltd.